PharmAust chief executive Michael Thurn has walked away from the top job, weeks after the clinical-stage biotech retracted his comments regarding a sales target for its re-purposed veterinary drug.
Cheyanne Enciso
Perth clinical-stage biotech PYC Therapeutics is gearing up to progress its drug aimed at treating polycystic kidney disease to human trials.
A listed Australian biopharmaceutical development company says it has the potential to provide the world’s first approved cannabinoid drug therapy for neurological disorders, like autism, in children.
Perth clinical dermatology company Botanix has been elevated into the All Ordinaries index made up of the top 500 companies listed on the Australian Securities Exchange.
Shares in a telehealth startup founded by neuroscientists at Princeton University have had a strong start to life on the Australian Securities Exchange, surging over 30 per cent.
The boss of PharmAust says it could offer hope to the hundreds of thousands of patients with motor neurone disease and ALS using a re-purposed veterinary drug.
Shares in Osteopore rallied as high as 900 per cent after the medtech company announced it had secured market approvals for its orthopaedic products in Singapore and Vietnam.
Regenerative medicine company Orthocell says it has successfully completed the first stage of a pivotal US market authorisation study for its nerve repair product, paving the way for global expansion.
From corporate and resources lawyer to executive director of a dermatology company, Matt Callahan has worn multiple hats during his 30-year career.
BlinkLab is seeking $7 million from new investors to commercialise a smartphone app that helps diagnose autism and ADHD in young children.
Sean Smith
The $3.5m of shares have been taken up by prominent investors Chris Ellison, Rod Jones, Malcolm and Tonya McCusker and Michael Malone, along with the Merchant Biotech Fund.
Psychedelic-assisted psychotherapy laws in the UK have dashed Little Green Pharma subsidiary Reset Mind Sciences’ hopes of listing on London’s AIM stock exchange.
Perth med tech company REX Ortho has unveiled its partnership with Switzerland-based AO Foundation, a deal it says will put Australia on the map for orthopaedic surgical device innovation.
PYC Therapeutics is laser-focused on only curing single-gene disorders in order to give the company the best chance of successfully launching its drug aimed at treating a degenerative eye disease.
Perth-based startup Uluu has launched its first-ever commercial collaboration with Australian surfwear brand Quiksilver.
Perth-based regenerative medicine company Orthocell has appointed former US ambassador and WA governor Kim Beazley to its board.
Lixa boss Maud Eijkenboom says she is on a mission to resolve a global rise in antibiotic resistance, which is already narrowing the range of medicines available to treat common illnesses.
Little Green Pharma’s psychedelics arm has kicked off a clinical trial using psilocybin for patients with treatment-resistant depression.
Up to 30,000 patients in WA who suffer from post-traumatic stress disorder could soon be prescribed MDMA after a Perth biotech was granted a crucial approval from the Therapeutic Goods Administration.
Biotech companies face a tough sell to investors but WA industry bosses are confident the healthcare sector will prove resilient amid a weaker economy as they aim to hit milestones in 2024.
Perth biotech Botanix is having another crack at entering the lucrative US market with its gel aimed at treating excessive sweating.
Perth biotech Botanix says it is now eyeing approval from the US Food and Drug Administration for its gel aimed at treating excessive sweating in mid-2024.
Further testing of a potentially breakthrough scar treatment is in the works after UWA researchers found the Pharmaxis-piloted topical topical cream to be safe for human application.
Jordan Murray
